NCT01892930已完成不适用
Immunologic Impact of Stereotactic Body Radiation Therapy (SBRT) in Renal Cell Carcinoma
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- Feasibility of conducting a partial nephrectomy in patients with no prior stereotactic radiation for kidney cancer
研究概览
简要总结
This pilot clinical trial studies stereotactic body radiation therapy in treating patients with metastatic kidney cancer undergoing surgery. Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
详细描述
PRIMARY OBJECTIVES:
I. Assess the impact of stereotactic body radiation therapy (SBRT) on the immune system in patients with metastatic renal cell carcinoma (RCC).
SECONDARY OBJECTIVES:
I. Assess changes in immune parameters prior to radiation, post radiation and post nephrectomy.
TERTIARY OBJECTIVES:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have metastatic RCC with primary tumor in place
- •Must be surgical candidates as deemed fit by surgeon
- •Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present
- •Patients of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
- •Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
排除标准
- •Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •Radiation to primary tumor prior to enrollment in this study
- •Pregnant or nursing female patients
- •Unwilling or unable to follow protocol requirements
- •Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive treatment
- •Received an investigational agent within 30 days prior to enrollment
结局指标
主要结局
Feasibility of conducting a partial nephrectomy in patients with no prior stereotactic radiation for kidney cancer
时间窗: Up to 30 days post-treatment
次要结局
- Toxicity analysis assessed by the CTEP Version 4 of the NCI Common Terminology Criteria for Adverse Events (CTCAE)(Up to 30 days post-treatment)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
早期 1 期
Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung CancerRecurrent Non-small Cell Lung CancerStage IIIA Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerNCT01781741Roswell Park Cancer Institute10
进行中（未招募）
早期 1 期
Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung CancerStage I Non-Small Cell Lung Cancer AJCC v7Stage IA Non-Small Cell Lung Carcinoma AJCC v7Stage IB Non-Small Cell Lung Carcinoma AJCC v7Stage II Non-Small Cell Lung Cancer AJCC v7Stage IIA Non-Small Cell Lung Carcinoma AJCC v7Stage IIB Non-Small Cell Lung Carcinoma AJCC v7Stage IIIA Non-Small Cell Lung Cancer AJCC v7NCT03348748Roswell Park Cancer Institute20
终止
不适用
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney CancerMetastatic Renal Cell CancerRecurrent Renal Cell CarcinomaStage IV Renal Cell CancerNCT02542202University of Chicago25
已完成
2 期
Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) EffectMetastatic Nonsmall Cell Lung CancerNon Small Cell Lung CancerNCT03825510Crozer-Keystone Health System3
进行中（未招募）
2 期
Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone SurgeryNCT03541850Jonsson Comprehensive Cancer Center92